Patents by Inventor Charles A. Sutherland

Charles A. Sutherland has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 5468898
    Abstract: This invention relates to bicyclic aryl compounds having selective LTB.sub.4 antagonist properties and comprising an amido substituent, a substituent group having a terminal carboxylic acid or derivative thereof and a lipophilic substituent, and to methods for the treatment of disorders which result from LTB.sub.4 activity and pharmaceutical compositions including such compounds.
    Type: Grant
    Filed: April 23, 1993
    Date of Patent: November 21, 1995
    Assignee: Rhone-Poulenc Rorer Pharmaceuticals Inc.
    Inventors: Fu-Chih Huang, Wan K. Chan, Charles A. Sutherland, Robert A. Galemmo, Jr.
  • Patent number: 5232948
    Abstract: Monocyclic aryl compounds having selective LTB.sub.4 antagonists properties and comprising an amido substituent, a substituent group having a terminal carboxylic acid or derivative thereof and a lipophilic substituent, therapeutic compositions and methods of treatment of disorders which result from LTB.sub.4 activity using the monocyclic aryl compounds are disclosed.
    Type: Grant
    Filed: September 10, 1990
    Date of Patent: August 3, 1993
    Assignee: Rhone-Poulenc Rorer Pharmaceuticals Inc.
    Inventors: Fu-Chih Huang, Wan K. Chan, Charles A. Sutherland, Robert A. Galemmo, Jr., Michael N. Chang
  • Patent number: 5210208
    Abstract: Monocyclic and bicyclic aryl ring compounds having selective LTB.sub.4 properties and comprising two ring substituents, the first substituent comprising a lipophilic group and a terminal carboxylic acid or derivative group, and the second substituent comprising an amido group, therapeutic compositions and methods of treatment of disorders which result from LTB.sub.4 activity using the mono- and bicyclic aryl compounds are disclosed.
    Type: Grant
    Filed: September 24, 1990
    Date of Patent: May 11, 1993
    Assignee: Rhone-Poulenc Rorer Pharmaceuticals Inc.
    Inventors: Fu-Chih Huang, Wan K. Chan, Charles A. Sutherland, Robert A. Galemmo, Jr., Michael N. Chang
  • Patent number: 4930757
    Abstract: A tuyere for a metallurgical vessel comprising a solid metal tuyere body with a central gas feed bore. The gas feed bore contains at least one gas feed pipe. The tuyere body also has at least one water-cooled bore between the outer wall of the tuyere body and the gas feed bore. A water-cooled bore has a water passage for circulating water therethrough. A water cooling header with separated water inlet and outlet is attached to the tuyere body external to the metallurgical vessel. A water passage is provided for a flow of water from the water inlet through the water passage in the water-cooled bore to the water outlet. The cooling capacity of the tuyere is sufficient to cause the formation of a protective encrustation on the end of the tuyere, and to effectively reduce erosion and chemical reaction of the tuyere material and the vessel wall.
    Type: Grant
    Filed: October 2, 1989
    Date of Patent: June 5, 1990
    Assignee: Cominco Ltd.
    Inventors: Robert E. Manwell, Charles A. Sutherland
  • Patent number: 4579865
    Abstract: Compounds of the structure; ##STR1## and pharmaceutically acceptable salts thereof, wherein:R.sub.1 is H, alkyl, alkoxy, carboxyl, alkylcarboxy, trifluoromethyl, halogen, nitro or hydroxy;X is O, N, S or C;Y is O, N or S; andR.sub.2 is H, alkyl, cycloalkyl, aryl or heteroaryl useful in the treatment of ischemic heart disease and hypertriglyceridemia.
    Type: Grant
    Filed: March 28, 1984
    Date of Patent: April 1, 1986
    Assignee: USV Pharmaceutical Corp.
    Inventors: John H. Musser, Charles A. Sutherland
  • Patent number: 4547509
    Abstract: Compounds of the structure ##STR1## and pharmaceutically acceptable salts thereof wherein: R.sub.1 is H, alkyl, alkoxy, carboxyl, alkylcarboxy, acylamino, dialkyl amino, trihalomethyl, halogen, nitro, hydroxy or cyano;X is in the 5, 6 or 7 position and is O(CH.sub.2).sub.n, N(CH.sub.2).sub.n --R.sub.3, S(CH.sub.2).sub.n or (CH.sub.2).sub.n ;Y is O(CH.sub.2).sub.n, S(CH.sub.2).sub.n, N(CH.sub.2).sub.n --R.sub.3 where R.sub.3 is H, alkyl or (CH.sub.2).sub.n ;R.sub.2 is monosubstituted or independently disubstituted H, hydroxy, alkyl, halogen, nitro, alkoxy, carboxyl, alkylcarboxy, trihalomethyl, cyano, trifluoromethyl, dialkylamino or acylamino;Z is O, S or (NR.sub.3).sub.2 where R.sub.3 is H, alkyl or aryl; andn is 0 to 10 inclusiveuseful in the treatment of ischemic heart disease and hypertriglyceridemia.
    Type: Grant
    Filed: January 3, 1983
    Date of Patent: October 15, 1985
    Assignee: USV Pharmaceutical Corp.
    Inventors: John H. Musser, Charles A. Sutherland
  • Patent number: 4530931
    Abstract: X is in the 8 position and is O(CH.sub.2).sub.n, N(CH.sub.2).sub.n ;Y is O(CH.sub.2).sub.n, N(CH.sub.2).sub.n ;R.sub.2 is monosubstituted or independently disubstituted H, carboxyl, or alkylcarboxy;Z is 0; andn is 0 to 10 inclusive,useful in the treatment of ischemic heart disease and hypertriglyceridemia.
    Type: Grant
    Filed: March 21, 1984
    Date of Patent: July 23, 1985
    Assignee: USV Pharmaceutical Corp.
    Inventors: John H. Musser, Charles A. Sutherland